Homepage > Company > Media > Pharma News > 2022 > Health Canada Approves Plant-Based COVID-19 Vaccine

Health Canada Approves Plant-Based COVID-19 Vaccine

Health Canada has approved Medicago’s Covifenz COVID-19 two-dose vaccine, the first authorized vaccine that uses plant-based proteins.

The vaccine, which is authorized for people aged 18 to 64 years old, was found to be 71 percent effective against symptomatic infection and 100 percent effective against severe disease in clinical trials. Each 3.75-mg dose is meant to be administered 21 days apart.

Health Canada noted that there was limited enrollment of people 65 and older in the Covifenz study since most of this age group was already vaccinated. Medicago is currently collecting data on older adults to support authorization for this age bracket.

In addition, the company must provide confirmatory safety and efficacy data on current and emerging variants. The preliminary data suggested Covifenz induced neutralizing antibodies against Omicron.

February 28, 2022

https://www.fdanews.com/

Read also

UK and US agree on landmark pharma pricing tariff deal

The UK and US have agreed to keep tariffs on UK pharmaceutical shipments into the US at zero.

Parkinson's drug as basis for new anti-infectives

Pseudomonas aeruginosa – one of the most common hospital germs – has sophisticated mechanisms to efficiently infect the human body and evade the immune system or antibiotics.

Modified herpes virus helps destroy glioblastoma in preclinical models

Researchers at Mass General Brigham have modified a herpes simplex virus (HSV-1) that stimulates the immune system to attack glioblastoma cells.

Curi Bio: $10 Million Series B Closed To Scale Human-Relevant Preclinical Platforms

Curi Bio has secured a $10 million Series B round led by Seoul-based contract research organization DreamCIS, funding that will accelerate the expansion of the company’s integrated human-relevant pr...